(Q37995569)

26 August 2017

title

Peroxisome proliferator-activated receptor gamma (PPAR-γ) and neurodegenerative disorders (English)

1 reference

26 August 2017

1 reference

Yu-Chang Chen

1

1 reference

26 August 2017

Jui-Sheng Wu

2

1 reference

26 August 2017

Hsin-Da Tsai

3

1 reference

26 August 2017

Chien-Yu Huang

4

1 reference

26 August 2017

Jin-Jer Chen

5

1 reference

26 August 2017

Grace Y Sun

6

1 reference

26 August 2017

Teng-Nan Lin

7

1 reference

26 August 2017

publication date

21 March 2012

1 reference

26 August 2017

published in

Molecular Neurobiology

1 reference

26 August 2017

volume

46

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

114-124

1 reference

MicroRNAs and deregulated gene expression networks in neurodegeneration

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Should the word 'dementia' be forgotten?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Interaction between pathogenic proteins in neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Peroxisome proliferator-activated receptor gamma and metabolic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

The mechanisms of action of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Lipid signalling in disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Peroxisome proliferator-activated receptors and angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

PPAR Regulation of Inflammatory Signaling in CNS Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

PPARs: the vasculature, inflammation and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

PPARs and the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

15d-prostaglandin J2 protects brain from ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

MRI monitoring of focal cerebral ischemia in peroxisome proliferator-activated receptor (PPAR)-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

PPAR gamma and human metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Rat peroxisome proliferator-activated receptors and brown adipose tissue function during cold acclimatization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Genetic analysis of four novel peroxisome proliferator activated receptor-gamma splice variants in monkey macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Identification and regulation of novel PPAR-gamma splice variants in human THP-1 macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Anti-apoptotic actions of PPAR-gamma against ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

PPARgamma and its ligands: therapeutic implications in cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

15d-Prostaglandin J2 activates peroxisome proliferator-activated receptor-gamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Safety issues and prospects for future generations of PPAR modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Rosiglitazone and the risk of adverse cardiovascular outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

15d-PGJ2: the anti-inflammatory prostaglandin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

The CCAAT/enhancer (C/EBP) family of basic-leucine zipper (bZIP) transcription factors is a multifaceted highly-regulated system for gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

CAAT/enhancer binding proteins directly modulate transcription from the peroxisome proliferator-activated receptor gamma 2 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Shared principles in NF-kappaB signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Structure of an IkappaBalpha/NF-kappaB complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Crosstalk in NF-κB signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Multiple nuclear factors interact with the immunoglobulin enhancer sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Regulation and function of NF-kappaB transcription factors in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Inflammation in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

PPAR-gamma: therapeutic target for ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

PPAR: a therapeutic target in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Transcribe to survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-012-8259-8

Basic mechanisms of neurodegeneration: a critical update

21 January 2018

1 reference

12 December 2020

Inflammation and Alzheimer's disease

1 reference

12 December 2020

Initiation and propagation of neurodegeneration

1 reference

12 December 2020

Photoreceptor phagocytosis selectively activates PPARgamma expression in retinal pigment epithelial cells

1 reference

12 December 2020

Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

1 reference

12 December 2020

10.1007/S12035-012-8259-8

Identifiers

DOI

1 reference

26 August 2017

1 reference